Open AccessEffects of PERK eIF2α Kinase Inhibitor against Toxoplasma gondii
Author(s) -
Leonardo Augusto,
Jennifer Martynowicz,
Kirk A. Staschke,
Ronald C. Wek,
William J. Sullivan
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01442-18
Subject(s) - toxoplasma gondii , kinase , pharmacology , virology , biology , microbiology and biotechnology , medicine , immunology , biochemistry , antibody
Toxoplasma gondii is an obligate intracellular parasite that has infected one-third of the population. Upon infection of warm-blooded vertebrates, the replicating form of the parasite (tachyzoite) converts into a latent form (bradyzoite) present in tissue cysts.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom